Clinical TrialMay 12, 2026, 10:34 AM
Syndax Revuforj shows strong activity in acute leukemia at EHA 2026
AI Summary
Syndax Pharmaceuticals announced the release of 12 Revuforj® (revumenib) abstracts for the European Hematology Association (EHA) 2026 Congress. The data highlights strong activity across various acute leukemia subtypes (KMT2Ar, NPM1m, NUP98r), compelling real-world outcomes, and favorable tolerability in both monotherapy and combination use. Encouraging results were also observed in the post-transplant setting and with frontline/relapsed/refractory combinations, bolstering confidence in Revuforj's potential to transform AML treatment.
Key Highlights
- Syndax released 12 Revuforj abstracts for the European Hematology Association (EHA) 2026 Congress.
- Abstracts highlight strong revumenib activity across acute leukemia treatment continuum and genetic subtypes.
- New real-world data show compelling outcomes and favorable tolerability with revumenib.
- Encouraging results observed with revumenib in the post-transplant setting.
- Frontline and R/R revumenib combination data show deep responses and robust transplant rates.
- Revuforj is FDA-approved for R/R acute leukemia with KMT2A translocation or NPM1 mutation.
- Multiple trials are ongoing or planned for revumenib in newly diagnosed patients.
Price Impact
More from SNDX